當(dāng)前位置：   首頁(yè) > 需求大廳

標(biāo)題：1000元懸賞提取國(guó)外上市醫(yī)藥企業(yè)年報(bào)中產(chǎn)品銷售數(shù)據(jù) 需求名稱：年報(bào)數(shù)據(jù)處理 價(jià)格預(yù)算：200元/人 詳細(xì)要求： ① 從任務(wù)主手中獲取指定企業(yè)的年報(bào)文件， ② 將年報(bào)中的相應(yīng)數(shù)據(jù)填入相應(yīng)表格，年報(bào)中沒有的數(shù)據(jù)表格相應(yīng)內(nèi)容不做填寫， ③ 要求仔細(xì)認(rèn)真，熟悉英文或?qū)Ψg工具的熟練使用， ④ 價(jià)格5元/個(gè)（填寫完了審核通過(guò)，每個(gè)年報(bào)要求把所有產(chǎn)品銷售額收集填寫完）， ⑤ 如若審核發(fā)現(xiàn)有填錯(cuò)，填漏；以每填錯(cuò)，填漏一個(gè)數(shù)據(jù)1元計(jì)量扣除賞金。 交稿方式：請(qǐng)將數(shù)據(jù)表格直接打包在藥智網(wǎng)交稿就可以了 交稿時(shí)間：可與任務(wù)主協(xié)商實(shí)際交稿時(shí)間。   [更多]

1. 熟悉PDF編輯技巧(去水印、去章印、增刪內(nèi)容) 2. 處理完213個(gè)PDF上面的水印標(biāo)記和部分與文章標(biāo)題無(wú)關(guān)的內(nèi)容，提交后待成品效果符合要求后才判為合格，否則為不合格任務(wù)（具體處理細(xì)則可以QQ咨詢） 3. 需處理的PDF文檔待接下任務(wù)后再提供 4. 以前投過(guò)稿且完成效果較好的優(yōu)先考慮   [更多]

標(biāo)題： 1、2015年美國(guó)CDC生殖器皰疹治療指南解讀 中國(guó)皮膚性病學(xué)雜志 2016年5月，第30卷第5期 530-3 2、Search for useful biomarkers in hepatocellular carcinoma, tumor factors and background liver factors (Review). 3、Biomarkers in hepatocellular carcinoma: an overview. 4、An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia. 5、Catalytic Michael/Ring-Closure Reaction of α,β-Unsaturated Pyrazoleamides with Amidomalonates: Asymmetric Synthesis of (?)- Paroxetine 6、Kumamoto, Koji; Ichikawa, Yoshiyasu; Kotsuki, Hiyoshizo Synlett, 2005 , # 14 art. no. U13805ST, p. 2254 - 2256 7、Smith, Brendan M.; Graham, Andrew E. Tetrahedron Letters, 2006 , vol. 47, # 52 p. 9317 - 9319 8、Comparison of antiplatelet and antithrombotic therapy for secondary prevention of ischemic stroke in patients with peripheral artery disease: population-based follow-up study in Taiwan. Lee WH, Chu CY, Hsu PC, Su HM, Lin TH, Voon WC, Lai WT, Sheu SH. Circ J. 2013;77(4):1046-52. Epub 2012 Dec 26. 9、Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Robertson L, Ghouri MA, Kovacs F. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002071. doi: 10.1002/14651858.CD002071.pub3. Review. 10、Drug-drug interactions associated with antiplatelet therapy. 11、H. Kreitmair, Arch. exp. Path. Pharmak. 164, 346 (1932). 12、R.D. Haworth et al., j. chem. Soc. 1947, 176 13、Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. 14、Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. 15、鹽酸伐昔洛韋顆粒劑治療兒童水痘療效觀察 中華皮膚科雜志,2009, 42(8):584-585 16、鹽酸伐昔洛韋治療兒童水痘療效觀察 中國(guó)醫(yī)師進(jìn)修雜志2011年4月25日第34卷第12期51-2 將符合標(biāo)題的文獻(xiàn)PDF格式上傳，按照交稿時(shí)間的先后確認(rèn)稿件，先到先得   [更多]

求厄貝沙坦片BP2017版及USP40藥典標(biāo)準(zhǔn)信息   [更多]

標(biāo)準(zhǔn)PDF文件，字跡清楚，可復(fù)制。   [更多]

標(biāo)準(zhǔn)PDF文件，字跡清楚，可復(fù)制。   [更多]

標(biāo)準(zhǔn)PDF文件，字跡清楚，可復(fù)制。   [更多]

復(fù)方黨參片信息，PDF格式或照片均可   [更多]

標(biāo)題： 1、Intern Med J. 2018 Jan;48 Suppl 1:5-12. doi: 10.1111/imj.13682. Diagnosis and management of hyponatraemia in the older patient. Woodward M1,2, Gonski P3, Grossmann M2, Obeid J4, Scholes R5, Topliss DJ6,7. 2、Heart Fail Clin. 2012 Jan;8(1):33-42. doi: 10.1016/j.hfc.2011.08.013. Volume overload. Carabello BA1. 3、Soriana F ，et al.Comparative susceptility of cefminox and cefotin to β-lactamases of Bacteroides spp J Amimincrob Chem-other 1991;28:55-56 4、Aguilar L,et al.Cefminox correlation between in-vitro susceptibility and pharmacokinetices and serum bactericidal activity in healthy volunteers. J Antimicrob Chemother 1994；33:91-101 5、Torres AJ, et al. Cefminox versus metronidazole plus gentamicin in intra-abdominal infections a prospective randomized controlled clinical trial Infection 2000.28:318-22 6、Ascorbate oxidase: The unexpected involvement of a ‘wasteful enzyme’ in the symbioses with nitrogen-fixing bacteria and arbuscular mycorrhizal fungi 7、Chapter?Twelve:?Integrated?and?Quantitative?Proteomics?of?Human?Tumors 8、 CHSY1?promotes?aggressive?phenotypes?of?hepatocellular?carcinoma?cells?via?activation?of?the?hedgehog?signa ling?pathway 9、 Transporter?expression?in?noncancerous?and?cancerous?liver?tissue?from?subjects?with?hepatocellular?carcinoma?and?chronic?hepatitis?C?in 10、J, Brange,L, Langkjaer.Chemical stability of insulin. 3. Influence of excipients, formulation, and pH.[J].Acta pharmaceutica 要求：將符合標(biāo)題的PDF格式上傳，根據(jù)投稿時(shí)間確認(rèn)稿件，先到先得   [更多]

完整的Fluticasone Propionate Lotion美國(guó)藥典標(biāo)準(zhǔn)，藥典版本不限，越新越好   [更多]